

## Special Issue

# Immune-Mediated Diseases Following Vaccination

### Message from the Guest Editor

Vaccination is very effective in preventing infectious diseases, and its practice has markedly reduced the morbidity and mortality caused by potentially severe infectious diseases. However, vaccination may be associated with adverse events, which may vary from injection site reactions to life-threatening allergic reactions. Vaccination, as the surrogate of an infectious disease inducing an immune reaction, may also trigger the development of immune-mediated diseases and atopic disorders. A number of autoimmune or immune-related disorders have been described to have been triggered by vaccination, particularly with the most widespread vaccination procedure (e.g., influenza and COVID-19). This Special Issue welcomes manuscripts describing and/or reviewing the current knowledge on the epidemiology, pathogenesis, clinical features, and treatment of immune-mediated disorders or atopic diseases induced or exacerbated by vaccination.

### Guest Editor

Prof. Dr. Giampiero Girolomoni

Division of Dermatology and Venereology, Department of Medicine,  
University of Verona, Piazzale A. Stefani 1, I-37126 Verona, Italy

### Deadline for manuscript submissions

31 December 2025



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/228250](https://mdpi.com/si/228250)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).